Near-Elimination of Otitis Media Caused by 13-Valent Pneumococcal Conjugate Vaccine (PCV) Serotypes in Southern Israel Shortly After Sequential Introduction of 7-Valent/13-Valent PCV

被引:138
|
作者
Ben-Shimol, Shalom [1 ,3 ]
Givon-Lavi, Noga [1 ,3 ]
Leibovitz, Eugene [1 ,3 ]
Raiz, Simon [2 ,3 ]
Greenberg, David [1 ,3 ]
Dagan, Ron [1 ,3 ]
机构
[1] Soroka Univ, Med Ctr, Pediat Infect Dis Unit, Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Dept Otolaryngol, Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
关键词
Streptococcus pneumonia; otitis media; pneumococcal conjugate vaccine; children; surveillance; STREPTOCOCCUS-PNEUMONIAE; CONTROLLED-TRIAL; CHILDREN; EFFICACY; DISEASE; IMPACT; INFANTS; IMMUNOGENICITY; IMMUNIZATION; INFECTIONS;
D O I
10.1093/cid/ciu683
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Otitis media (OM) is common in early childhood. Streptococcus pneumoniae caused approximately 30%-60% of episodes before the pneumococcal conjugate vaccine (PCV) era. The 7-valent PCV (PCV7) was introduced to the Israeli National Immunization Plan in July 2009, and was gradually replaced by the 13-valent PCV (PCV13) starting in November 2010. We aimed at assessing the impact of PCV7/PCV13 sequential introduction on pneumococcal and overall OM necessitating middle ear fluid culture in children aged <2 years in southern Israel. Methods. This was a prospective, population-based, active surveillance. Our medical center is the only one in the region, enabling incidence calculation. All pneumococcal episodes submitted for culture between July 2004 and June 2013 were included. Three subperiods were defined: pre-PCV, PCV7, and PCV13. Results. Overall, 6122 OM episodes were recorded, and 1893 were pneumococcal. Compared with the pre-PCV period, OM caused by PCV7 plus serotype 6A and the 5 additional PCV13 serotypes (5VT : 1, 3, 5, 7F, 19A) decreased by 96% and 85%, respectively (incidence rate ratios [IRRs], 0.04 [95% confidence interval {CI},.02-.08] and 0.15 [95% CI,.07-.30], respectively) in a 2-step pattern: In the PCV7 period, only OM caused by PCV7 + 6A serotypes was decreased; in the PCV13 period, 5VT OM rates decreased, along with an additional PCV7 + 6A OM reduction. A nonsignificant increase in non-PCV13 serotype OM was observed (IRR, 1.07 [95% CI,.72-1.58]). In total, 77% and 60% reductions of all-pneumococcal and all-cause OM incidences, respectively, were observed. Conclusions. A substantial 2-step reduction of pneumococcal OM rates, with near-elimination of PCV13 disease, was observed shortly after PCV7/PCV13 introduction.
引用
收藏
页码:1724 / 1732
页数:9
相关论文
共 50 条
  • [1] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [2] Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible Streptococcus pneumoniae
    Dagan, Ron
    Juergens, Christine
    Trammel, James
    Patterson, Scott
    Greenberg, David
    Givon-Lavi, Noga
    Porat, Nurith
    Gurtman, Alejandra
    Gruber, William C.
    Scott, Daniel A.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (07) : 1144 - 1153
  • [3] Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology
    Zhao, Alice S.
    Boyle, Sean
    Butrymowicz, Anna
    Engle, Robert D.
    Roberts, Jason M.
    Mouzakes, Jason
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2014, 78 (03) : 499 - 503
  • [4] Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Miller, Elizabeth
    Andrews, Nicholas J.
    Waight, Pauline A.
    Slack, Mary P. E.
    George, Robert C.
    VACCINE, 2011, 29 (49) : 9127 - 9131
  • [5] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Ricketson, Leah J.
    Bettinger, Julie A.
    Sadarangani, Manish
    Halperin, Scott A.
    Kellner, James D.
    VACCINE, 2022, 40 (19) : 2733 - 2740
  • [6] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Yeh, Sylvia H.
    London, Arnold
    Sidhu, Mohinder S.
    Patterson, Scott
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (12) : 1086 - 1091
  • [7] 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial
    Silfverdal, Sven Arne
    Flodmark, Carl-Erik
    Rombo, Lars
    Tansey, Susan P.
    Sidhu, Mohinder
    Trammel, James
    Emini, Emilio A.
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    VACCINE, 2013, 31 (09) : 1284 - 1292
  • [8] Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults
    Gaillat, J.
    MEDECINE ET MALADIES INFECTIEUSES, 2013, 43 (06): : 215 - 221
  • [9] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China
    Zhu, Fengcai
    Hu, Yuemei
    Li, Jingxin
    Ye, Qiang
    Young, Mariano M., Jr.
    Zhou, Xin
    Chen, Zhangjing
    Yan, Bing
    Liang, John Z.
    Gruber, William C.
    Giardina, Peter C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) : 999 - 1010
  • [10] 13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Naive to 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Senders, Shelly
    Harris-Ford, Laurie
    Sperling, Malcolm
    Patterson, Scott
    Devlin, Carmel
    Jansen, Kathrin U.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : 183 - 189